Literature DB >> 22552978

Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group.

R Aplenc1, B T Fisher, Y S Huang, Y Li, T A Alonzo, R B Gerbing, M Hall, D Bertoch, R Keren, A E Seif, L Sung, P C Adamson, A Gamis.   

Abstract

PURPOSE: The National Cancer Institute-funded cooperative oncology group trials have improved overall survival for children with cancer from 10% to 85% and have set standards of care for adults with malignancies. Despite these successes, cooperative oncology groups currently face substantial challenges. We are working to develop methods to improve the efficiency and effectiveness of these trials. Specifically, we merged data from the Children's Oncology Group (COG) and the Pediatric Health Information Systems (PHIS) to improve toxicity monitoring, to estimate treatment-associated resource utilization and costs, and to address important clinical epidemiology questions.
METHODS: COG and PHIS data on patients enrolled on a phase III COG trial for de novo acute myeloid leukemia at 43 PHIS hospitals were merged using a probabilistic algorithm. Resource utilization summary statistics were then tabulated for the first chemotherapy course based on PHIS data.
RESULTS: Of 416 patients enrolled on the phase III COG trial at PHIS centers, 392 (94%) were successfully matched. Of these, 378 (96%) had inpatient PHIS data available beginning at the date of study enrollment. For these, daily blood product usage and anti-infective exposures were tabulated and standardized costs were described.
CONCLUSIONS: These data demonstrate that patients enrolled in a cooperative group oncology trial can be successfully identified in an administrative data set and that supportive care resource utilization can be described. Further work is required to optimize the merging algorithm, map resource utilization metrics to the National Cancer Institute Common Toxicity Criteria for monitoring toxicity, to perform comparative effectiveness studies, and to estimate the costs associated with protocol therapy.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22552978      PMCID: PMC3359580          DOI: 10.1002/pds.3241

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  15 in total

1.  Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study.

Authors:  Brian T Fisher; Theoklis E Zaoutis; Kateri H Leckerman; Russell Localio; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

Review 2.  Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data.

Authors:  Eric I Benchimol; Douglas G Manuel; Teresa To; Anne M Griffiths; Linda Rabeneck; Astrid Guttmann
Journal:  J Clin Epidemiol       Date:  2010-12-30       Impact factor: 6.437

3.  Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications.

Authors:  Lee D Kaiser; Allen S Melemed; Alaknanda J Preston; Hilary A Chaudri Ross; Donna Niedzwiecki; Gwendolyn A Fyfe; Jacqueline M Gough; William D Bushnell; Cynthia L Stephens; M Kelsey Mace; Jeffrey S Abrams; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

4.  Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.

Authors:  Michelle R Mahoney; Daniel J Sargent; Michael J O'Connell; Richard M Goldberg; Paul Schaefer; Jan C Buckner
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

5.  Hospital resource utilization in childhood cancer.

Authors:  Marc B Rosenman; Terry Vik; Siu L Hui; Philip P Breitfeld
Journal:  J Pediatr Hematol Oncol       Date:  2005-06       Impact factor: 1.289

6.  AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Todd M Cooper; Janet Franklin; Robert B Gerbing; Todd A Alonzo; Craig Hurwitz; Susana C Raimondi; Betsy Hirsch; Franklin O Smith; Prasad Mathew; Robert J Arceci; James Feusner; Robert Iannone; Robert S Lavey; Soheil Meshinchi; Alan Gamis
Journal:  Cancer       Date:  2011-07-15       Impact factor: 6.860

7.  Adverse event reporting in publications compared with sponsor database for cancer clinical trials.

Authors:  Orit Scharf; A Dimitrios Colevas
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

8.  Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

Authors:  Elizabeth B Lamont; James E Herndon; Jane C Weeks; I Craig Henderson; Rogerio Lilenbaum; Richard L Schilsky; Nicholas A Christakis
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

9.  Appendicitis 2000: variability in practice, outcomes, and resource utilization at thirty pediatric hospitals.

Authors:  Kurt Newman; Todd Ponsky; Kory Kittle; Lorna Dyk; Cheri Throop; Karen Gieseker; Marion Sills; James Gilbert
Journal:  J Pediatr Surg       Date:  2003-03       Impact factor: 2.545

10.  Cefepime and mortality in pediatric acute myelogenous leukemia: a retrospective cohort study.

Authors:  Brian T Fisher; Richard Aplenc; Russell Localio; Kateri H Leckerman; Theoklis E Zaoutis
Journal:  Pediatr Infect Dis J       Date:  2009-11       Impact factor: 2.129

View more
  30 in total

1.  Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.

Authors:  Tamara P Miller; Brian T Fisher; Kelly D Getz; Leah Sack; Hanieh Razzaghi; Alix E Seif; Rochelle Bagatell; Peter C Adamson; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2019-04-09       Impact factor: 3.167

2.  Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.

Authors:  Marko Kavcic; Brian T Fisher; Yimei Li; Alix E Seif; Kari Torp; Dana M Walker; Yuan-Shung Huang; Grace E Lee; Sarah K Tasian; Marijana Vujkovic; Rochelle Bagatell; Richard Aplenc
Journal:  Cancer       Date:  2013-02-21       Impact factor: 6.860

3.  Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Tamara P Miller; Yimei Li; Marko Kavcic; Kelly D Getz; Yuan-Shun V Huang; Lillian Sung; Todd A Alonzo; Robert Gerbing; Marla H Daves; Terzah M Horton; Michael A Pulsipher; Jessica Pollard; Rochelle Bagatell; Alix E Seif; Brian T Fisher; Selina Luger; Alan S Gamis; Peter C Adamson; Richard Aplenc
Journal:  Haematologica       Date:  2017-06-22       Impact factor: 9.941

4.  Comparable on-therapy mortality and supportive care requirements in Black and White patients following initial induction for pediatric acute myeloid leukemia.

Authors:  Yimei Li; Joanna G Newton; Kelly D Getz; Yuan-Shung Huang; Alix E Seif; Brian T Fisher; Richard Aplenc; Lena E Winestone
Journal:  Pediatr Blood Cancer       Date:  2018-12-26       Impact factor: 3.167

5.  Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.

Authors:  Lena E Winestone; Kelly D Getz; Pooja Rao; Yimei Li; Matt Hall; Yuan-Shung V Huang; Alix E Seif; Brian T Fisher; Richard Aplenc
Journal:  Leuk Lymphoma       Date:  2019-02-07

6.  Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.

Authors:  Tamara P Miller; Andrea B Troxel; Yimei Li; Yuan-Shung Huang; Todd A Alonzo; Robert B Gerbing; Matt Hall; Kari Torp; Brian T Fisher; Rochelle Bagatell; Alix E Seif; Lillian Sung; Alan Gamis; David Rubin; Selina Luger; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2015-03-11       Impact factor: 3.167

7.  The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis.

Authors:  Staci D Arnold; Ruta Brazauskas; Naya He; Yimei Li; Matt Hall; Yoshiko Atsuta; Jignesh Dalal; Theresa Hahn; Nandita Khera; Carmem Bonfim; Shahrukh Hashmi; Susan Parsons; William A Wood; Amir Steinberg; César O Freytes; Christopher E Dandoy; David I Marks; Hillard M Lazarus; Hisham Abdel-Azim; Menachem Bitan; Miguel Angel Diaz; Richard F Olsson; Usama Gergis; Adriana Seber; Baldeep Wirk; C Fred LeMaistre; Celalettin Ustun; Christine Duncan; David Rizzieri; David Szwajcer; Franca Fagioli; Haydar Frangoul; Jennifer M Knight; Rammurti T Kamble; Paulette Mehta; Raquel Schears; Prakash Satwani; Michael A Pulsipher; Richard Aplenc; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-25       Impact factor: 5.742

8.  Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States.

Authors:  Shannon L Maude; Julie C Fitzgerald; Brian T Fisher; Yimei Li; Yuan-Shung Huang; Kari Torp; Alix E Seif; Marko Kavcic; Dana M Walker; Kateri H Leckerman; Todd J Kilbaugh; Susan R Rheingold; Lillian Sung; Theoklis E Zaoutis; Robert A Berg; Vinay M Nadkarni; Neal J Thomas; Richard Aplenc
Journal:  Pediatr Crit Care Med       Date:  2014-02       Impact factor: 3.624

9.  Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009.

Authors:  Brian T Fisher; Sonia Singh; Yuan-Shung Huang; Yimei Li; John Gregory; Dana Walker; Alix E Seif; Marko Kavcic; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2013-07-18       Impact factor: 3.167

10.  Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals.

Authors:  Pooja Rao; Yimei Li; Kelly D Getz; Tamara P Miller; Yuan-Shung Huang; Jennifer J Wilkes; Alix E Seif; Rochelle Bagatell; Brian T Fisher; Clarisa Gracia; Richard Aplenc
Journal:  Cancer       Date:  2016-09-12       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.